One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

Pfizer CEO ‌Albert ‌Bourla on Monday ​flagged issues with the leadership of ‌the ⁠U. Food and ⁠Drug Administration's vaccine ...

NEW YORK, March 5 (Reuters) - A federal judge on Thursday awarded Pfizer $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider ...

Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...

Is Pfizer stock the only big pharma name I'd buy and hold through any market crash? Let's find out. Image source: Getty ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer PFE faces several near-term challenges like declining COVID sales, the upcoming loss of exclusivity (“LOE”) cliff and U.S. Medicare Part D headwinds. These headwinds can hurt its sales and ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or hold?

Pfizer (PFE)-backed Priovant Therapeutics wins U.S. FDA's priority review for skin disorder therapy with a targeted action ...

By Mariam Sunny March 2 (Reuters) - Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad, in response to a ...